Tilray | TRLY - Cost Of Sales

Stock Price
10.62
Daily Change
-0.31 -2.84%
Monthly
-0.38%
Yearly
892.52%
Q1 Forecast
10.37

Tilray reported $164.37M in Cost of Sales for its fiscal quarter ending in September of 2025.





Cost Of Sales Change Date
Akebia Therapeutics USD 8.13M 2.41M Mar/2025
Alaunos Therapeutics USD 0 18K Sep/2024
Aurora Cannabis CAD 58.08M 11.99M Sep/2025
Avita Medical AUD 3.47M 1.19M Jun/2025
Canopy Growth CAD 44.78M 9.32M Sep/2025
Cronos Group USD 28.74M 10.38M Dec/2025
Divis Laboratories Ltd INR 10.63B 1.23B Dec/2025
Ionis Pharmaceuticals USD 8M 5.66M Dec/2025
IQVIA Holdings USD 3.24B 518M Dec/2025
Knight Therapeutics CAD 47.25M 990K Sep/2024
Moderna USD 452M 245M Dec/2025
Organigram Holdings CAD 77.46M 14.63M Sep/2025
Organon & Co USD 745M 25M Sep/2025
Revvity USD 350.4M 26.05M Dec/2025
Tilray USD 164.37M 8.41M Sep/2025
Viatris USD 2.56B 167.3M Dec/2025
Xeris Pharmaceuticals USD 13.71M 1.81M Sep/2025